Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (21-30 of 324) with videos related to

Pageof 33
Sort By:
The Lancet. HIV|May 9, 2017
Long-term durability of HIV viral load suppressionNila J Dharan, David A Cooper
New South Wales Public Health Bulletin|June 2, 2010
Clinical research in NSW: its role in HIV care and preventionDamien V Cordery, David A Cooper
The Lancet. Infectious Diseases|October 1, 2013
SPRING-2 the future of antiretroviral therapyMark A Boyd, David A Cooper
The Lancet. HIV|January 15, 2016
Novel antiretroviral agents and universal access to HIV careMark A Boyd, David A Cooper
The Lancet. Infectious Diseases|June 29, 2004
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and developmentDavid A Cooper, Joep M A Lange
Lancet (London, England)|July 21, 2009
Antiretroviral roll-out: the problem of second-line therapyMark Boyd, Sean Emery, David A Cooper
Journal of the International AIDS Society|September 11, 2014
In memoriam: Joep Lange MD, PhDChris Beyrer, Stefano Vella, David A Cooper
The Journal of Infectious Diseases|April 19, 2008
Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatmentDavid A Cooper, Sean Emery, Damien V Cordery
AIDS Research and Therapy|May 16, 2007
Predictors of disease progression in HIV infection: a reviewSimone E Langford, Jintanat Ananworanich, David A Cooper
Current Diabetes Reports|March 20, 2003
HIV-associated lipodystrophy: description, pathogenesis, and molecular pathwaysPatrick W G Mallon, Andrew Carr, David A Cooper
Pageof 33

Showing results (21-30 of 324) with videos related to

Sort By:
Pageof 33
The Lancet. HIV|May 9, 2017
Long-term durability of HIV viral load suppressionNila J Dharan, David A Cooper
New South Wales Public Health Bulletin|June 2, 2010
Clinical research in NSW: its role in HIV care and preventionDamien V Cordery, David A Cooper
The Lancet. Infectious Diseases|October 1, 2013
SPRING-2 the future of antiretroviral therapyMark A Boyd, David A Cooper
The Lancet. HIV|January 15, 2016
Novel antiretroviral agents and universal access to HIV careMark A Boyd, David A Cooper
The Lancet. Infectious Diseases|June 29, 2004
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and developmentDavid A Cooper, Joep M A Lange
Lancet (London, England)|July 21, 2009
Antiretroviral roll-out: the problem of second-line therapyMark Boyd, Sean Emery, David A Cooper
Journal of the International AIDS Society|September 11, 2014
In memoriam: Joep Lange MD, PhDChris Beyrer, Stefano Vella, David A Cooper
The Journal of Infectious Diseases|April 19, 2008
Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatmentDavid A Cooper, Sean Emery, Damien V Cordery
AIDS Research and Therapy|May 16, 2007
Predictors of disease progression in HIV infection: a reviewSimone E Langford, Jintanat Ananworanich, David A Cooper
Current Diabetes Reports|March 20, 2003
HIV-associated lipodystrophy: description, pathogenesis, and molecular pathwaysPatrick W G Mallon, Andrew Carr, David A Cooper
Pageof 33